Abstract
The first data from the phase III CheckMate-227 trial of ipilimumab plus nivolumab for the treatment of non–small cell lung cancer suggests that the two drugs boost progression-free survival in patients with a high tumor mutation burden. After 1 year, progression-free survival was 43% for patients treated with the checkpoint inhibitor combination, compared with 13% for patients treated with chemotherapy.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Published OnlineFirst April 16, 2018
doi: 10.1158/2159-8290.CD-NB2018-048
High TMB Predicts Immunotherapy Benefit in NSCLC
Jump to section
Advertisement